Choreo LLC Has $2.62 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Choreo LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.0% in the 4th quarter, Holdings Channel reports. The firm owned 3,714 shares of the biopharmaceutical company’s stock after selling 321 shares during the quarter. Choreo LLC’s holdings in Regeneron Pharmaceuticals were worth $2,619,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Tectonic Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 16.6% in the 4th quarter. Tectonic Advisors LLC now owns 830 shares of the biopharmaceutical company’s stock worth $591,000 after acquiring an additional 118 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 21.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 55,426 shares of the biopharmaceutical company’s stock worth $38,305,000 after purchasing an additional 9,845 shares during the period. Paragon Capital Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $1,257,000. 1858 Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $224,000. Finally, Avitas Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 12.7% during the 4th quarter. Avitas Wealth Management LLC now owns 372 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 42 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $722.07 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The firm’s 50 day moving average is $717.27 and its 200-day moving average is $914.93. The firm has a market capitalization of $79.35 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 1.60 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $11.86 earnings per share. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.49%. The ex-dividend date of this dividend is Thursday, February 20th.

Analysts Set New Price Targets

Several research firms have recently issued reports on REGN. Evercore ISI dropped their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Citigroup dropped their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.